Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.30 |
| ▸ | HTR1D | P28221 | 3/20 | 0.30 |
| ▸ | HTR2A | P28223 | 3/20 | 0.30 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6552858 | 0.91 | DAO (0.32) | TAAR1 | |
| SCHEMBL6552180 | 0.80 | TAAR1 (0.40) | TAAR1NOTUMPNMTDRD2HTR1D | |
| SCHEMBL6553050 | 0.76 | DRD2 (0.42) | DRD2HTR1D | |
| SCHEMBL6552901 | 0.76 | DRD2 (0.36) | DRD2HTR1D | |
| SCHEMBL5093705 | 0.76 | HTR1D (0.52) | DRD2HTR1DHTR2AHTR1ADRD4 | |
| SCHEMBL6811129 | 0.76 | HTR1D (0.52) | DRD2HTR1DHTR2AHTR1ADRD4 | |
| SCHEMBL6551590 | 0.74 | TAAR1 (0.59) | TAAR1DRD2HTR1A | |
| SCHEMBL6552136 | 0.72 | HPGD (0.35) | TAAR1DRD2HTR1DHTR2AHTR1A | |
| SCHEMBL6812077 | 0.71 | HTR1D (0.43) | DRD2HTR1DHTR2AHTR1ADRD4 | |
| SCHEMBL5097946 | 0.71 | HTR1D (0.43) | DRD2HTR1DHTR2AHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
| EP-1409476-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003006455-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | TAAR1 150/4885NOTUM 2325/4885PNMT 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.